Your browser is no longer supported. Please, upgrade your browser.
Settings
GILD Gilead Sciences, Inc. daily Stock Chart
GILD [NASD]
Gilead Sciences, Inc.
IndexS&P 500 P/E23.16 EPS (ttm)3.48 Insider Own0.30% Shs Outstand1.32B Perf Week1.74%
Market Cap106.50B Forward P/E12.18 EPS next Y6.63 Insider Trans-21.51% Shs Float1.30B Perf Month-0.58%
Income4.63B PEG- EPS next Q1.64 Inst Own80.80% Short Float1.73% Perf Quarter12.38%
Sales26.11B P/S4.08 EPS this Y-16.50% Inst Trans1.72% Short Ratio2.59 Perf Half Y11.56%
Book/sh19.02 P/B4.24 EPS next Y2.95% ROA20.40% Target Price88.68 Perf Year14.78%
Cash/sh21.51 P/C3.75 EPS next 5Y-7.35% ROE56.20% 52W Range63.76 - 89.54 Perf YTD12.65%
Dividend2.28 P/FCF9.87 EPS past 5Y41.20% ROI31.00% 52W High-9.24% Beta1.23
Dividend %2.83% Quick Ratio3.60 Sales past 5Y29.40% Gross Margin83.30% 52W Low27.46% ATR2.58
Employees9000 Current Ratio3.70 Sales Q/Q-13.20% Oper. Margin63.10% RSI (14)52.16 Volatility2.27% 3.30%
OptionableYes Debt/Eq1.18 EPS Q/Q-17.10% Profit Margin46.80% Rel Volume0.89 Prev Close80.70
ShortableYes LT Debt/Eq1.11 EarningsFeb 06 AMC Payout21.30% Avg Volume8.68M Price81.27
Recom2.20 SMA20-0.86% SMA503.98% SMA2008.56% Volume1,095,567 Change0.70%
Feb-12-18Reiterated Mizuho Buy $83 → $95
Feb-08-18Reiterated Citigroup Buy $103 → $105
Jan-26-18Upgrade Jefferies Hold → Buy
Jan-16-18Upgrade Wells Fargo Market Perform → Outperform
Dec-20-17Downgrade Credit Suisse Outperform → Neutral
Nov-30-17Upgrade Maxim Group Hold → Buy $94
Nov-13-17Downgrade Argus Buy → Hold
Nov-08-17Reiterated Mizuho Buy $77 → $83
Oct-11-17Resumed Barclays Overweight $90
Oct-05-17Initiated Oppenheimer Perform
Oct-04-17Resumed Jefferies Hold $93
Sep-15-17Initiated RBC Capital Mkts Outperform $94
Sep-05-17Reiterated Wells Fargo Market Perform $73 → $81
Aug-31-17Upgrade Argus Hold → Buy
Aug-31-17Resumed William Blair Outperform $87
Jul-11-17Resumed Jefferies Hold
Jun-23-17Initiated Deutsche Bank Buy $79
Mar-09-17Resumed UBS Neutral $118 → $72
Feb-08-17Downgrade Citigroup Buy → Neutral
Nov-14-16Initiated Stifel Buy $100
Feb-19-18 07:00AM  Is AbbVie or Gilead Sciences Stock a Better Buy? Motley Fool
Feb-17-18 12:18PM  Gilead wins reversal of $2.54 bln hepatitis C drug patent verdict Reuters
12:07PM  Gilead wins reversal of $2.54 billion hepatitis C drug patent verdict Reuters
10:31AM  How Celgene Hopes to Cash In on CAR-T Motley Fool
09:41AM  Gilead wins reversal of $2.54 bln hepatitis C drug patent verdict Reuters
Feb-16-18 05:18PM  Should You Be Concerned About Gilead Sciences Incs (NASDAQ:GILD) -65.72% Earnings Decline? Simply Wall St.
01:05PM  Why 2018 Could Be An Explosive Year For Biotech Mergers Investor's Business Daily
Feb-15-18 02:03PM  Here's why stocks are rallying and set for 5 straight days of gains: NYSE trader Yahoo Finance Video
08:20AM  Todays Research Reports on Trending Tickers: Gilead Sciences and Abbott Laboratories ACCESSWIRE
06:02AM  3 Great Acquisition Targets for Gilead Sciences -- and 1 Iffy Candidate Motley Fool
Feb-12-18 01:14PM  [$$] Big Buys of Amazon, GE, Walmart Stock Barrons.com
08:30AM  Todays Research Reports on Trending Tickers: Regeneron Pharmaceuticals and Gilead Sciences ACCESSWIRE
07:07AM  How Huge Is the Latest HIV Drug Approval for Gilead Sciences? Motley Fool
Feb-11-18 08:07AM  Why Biotech Stocks Soared in Trump's First Year in Office Motley Fool
Feb-10-18 02:33PM  3 ETFs to Watch on Biotech Earnings Zacks
Feb-08-18 06:48PM  Stock Market Drop Not Seen Dampening Healthcare Deal Activity TheStreet.com -5.49%
04:01PM  Gilead Sciences to Present at the RBC Capital Markets 2018 Global Healthcare Conference on Wednesday, February 21 Business Wire
01:35PM  Why Crispr Therapeutics AG Stock Bolted Higher in January Motley Fool
09:36AM  FDA Approves Gilead (GILD) HIV Triple Therapy, Stock Up Zacks
08:00AM  Gilead Versus Glaxo: See You In Court Forbes
07:30AM  Here's What Gilead Sciences Just Said About Its Future Motley Fool
07:20AM  Wired News Actinium Pharma Reported Trial to Study Actimab-A in Combination with CLAG-M for Relapsed or Refractory AML Patients ACCESSWIRE
04:30AM  Drugmaker GSK wins fresh Advair reprieve as Novartis copy delayed Reuters
Feb-07-18 09:17PM  U.S. FDA approves Gilead triple HIV drug, rival files lawsuit Reuters
06:09PM  U.S. FDA approves Gilead triple HIV drug, rival files lawsuit Reuters
05:59PM  "Fast Money" final trades: GILD, AAPL and more CNBC Videos
05:35PM  After blockbuster HIV drug intro, Gilead wins FDA OK for another drug to fight AIDS virus American City Business Journals
05:14PM  Gilead Pops After FDA Approves Glaxo-Rivaling HIV Drug Investor's Business Daily
04:46PM  U.S. FDA approves Gilead's three-drug HIV regimen Reuters
03:45PM  Gilead's once-a-day HIV regimen has been approved by FDA MarketWatch
03:26PM  Gilead Sciences, Inc. Notches FDA Approval for Biktarvy in HIV-1 SmarterAnalyst
03:26PM  Gilead Sciences: Investors Are Betting On A Better 2019 Forbes
03:04PM  U.S. FDA approves Gilead's three-drug HIV regimen Reuters
02:52PM  Only a handful of countries are backing a life-saving HIV-prevention drug Quartz
02:37PM  With $36.7B In Cash, Bank of America Expects Gilead To Shop For Complements To Drug Pipeline Benzinga
02:27PM  More buying in P&G, plus bulls bet on this biotech name CNBC Videos
02:23PM  5 Things Gilead Sciences' Management Just Said That You Need to Know Motley Fool
02:22PM  U.S. Food and Drug Administration Approves Gileads Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection Business Wire
12:25PM  Gilead stock climbs 5% as investors bet company is in a trough, not a plateau MarketWatch
09:02AM  Gilead (GILD) Beats on Q4 Earnings, 2018 View Lacks Lustre Zacks
07:36AM  The Zacks Analyst Blog Highlights: Walt Disney, Chipotle, Snap and Gilead Sciences Zacks
06:32AM  Gilead Sciences Inc. Delivers Deja Vu in the Fourth Quarter Motley Fool
Feb-06-18 08:43PM  Gilead Sciences Inc. (GILD) Q4 2017 Earnings Conference Call Transcript Motley Fool
05:51PM  New Quarterly Earnings Results for DIS, CMG, SNAP and More Zacks
05:50PM  Gilead 4th-qtr hepatitis C drug sales plummet, sees further slowdown Reuters
05:48PM  Gilead Beats Quarterly Views, But Topples On Soft 2018 Guidance Investor's Business Daily
05:42PM  Gilead Q4 hepatitis C drug sales plummet, shrs drop 3 pct after hours Reuters
05:24PM  Gilead (GILD) Posts Earnings Beat, Total Product Sales See YoY Decline Zacks
04:45PM  Gilead reports 4Q loss Associated Press
04:37PM  Gilead Slips as Sales of Blockbuster Hepatitis Drugs Fade Bloomberg
04:25PM  Gilead shares slide as outlook falls short MarketWatch
04:10PM  Gilead Sciences beats the Street CNBC Videos
04:02PM  Gilead Sciences Announces 10 Percent Increase in First Quarter 2018 Dividend Business Wire
04:01PM  Gilead Sciences Announces Fourth Quarter and Full Year 2017 Financial Results Business Wire
12:26PM  Earnings Outlook For Gilead Sciences Benzinga
12:01PM  The Diseases We Arent CuringAnd Why Fortune
12:00PM  Gilead Sciences, Inc. to Host Earnings Call ACCESSWIRE
09:39AM  How Does Gilead Sciences Inc (NASDAQ:GILD) Fare As A Dividend Stock? Simply Wall St.
Feb-05-18 10:42AM  Gilead Sciences to Release 4th-Quarter Earnings GuruFocus.com
08:49AM  Billionaire Fund Managers Are Bullish On These Biotech Stocks Insider Monkey
Feb-04-18 08:07AM  What to Expect With Gilead Sciences' Q4 Results Motley Fool
Feb-03-18 09:20AM  Top 5 Biotech Stocks for 2018 Investopedia
Feb-02-18 04:30PM  Biotech stocks hold up amid market sell-off CNBC Videos
08:16AM  Gilead's (GILD) HCV Segment to Decline Further in Q4 Earnings? Zacks
06:33AM  3 Top Biotherapeutics Stocks to Buy Now Motley Fool
Feb-01-18 04:05PM  Jacqueline K. Barton, Ph.D., Joins Gilead Sciences Board of Directors Business Wire
08:40AM  Will Gilead (GILD) Disappoint Investors in Q4 Earnings? Zacks
08:28AM  [$$] DowDuPont Unit Dumps GE Stock, Buys Ford Barrons.com
08:00AM  Market Trends Toward New Normal in Alexander's, Atrion, FS, Gilead Sciences, Abbott Laboratories, and Johnson & Johnson Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Jan-31-18 07:39PM  How Financially Strong Is Gilead Sciences Inc (NASDAQ:GILD)? Simply Wall St.
06:12AM  Vertex (VRTX) & Other Drug Stocks with FDA Catalysts this February Zacks
Jan-30-18 02:01PM  I'm very bullish on all the tech earnings this week: NYSE trader Yahoo Finance Video
12:59PM  Gilead Sciences Outlook Brightens; Citi Upgrades Benzinga
10:37AM  Winning In The Market With The Patience Of The Wright Brothers And Warren Buffett Forbes
08:04AM  3 Big Biotech Stocks With Major Catalysts on the Way Motley Fool
Jan-29-18 02:33PM  The biggest headwind for stocks since the election is now here Yahoo Finance Video
12:16AM  [$$] AbbVie Gives More Juice to Drug Rally The Wall Street Journal
Jan-27-18 03:17PM  3 Reasons Celgene's Investors Should Applaud the Juno Therapeutics Buyout Motley Fool
10:00AM  [$$] AbbVie Gives More Juice to Drug Rally The Wall Street Journal
Jan-26-18 05:25PM  "Fast Money" final trades: X, GILD, and more CNBC Videos +5.26%
03:31PM  Dont Chase AbbVie Inc Stock After Its Huge Earnings Win InvestorPlace
01:48PM  Jefferies On Gilead: 'We See Better Days Ahead' Benzinga
11:59AM  Is It Finally Safe to Buy Gilead Sciences Stock? 1 Analyst Thinks So Motley Fool
10:56AM  Don't Give Up on Gilead Yet Barrons.com
07:45AM  3 Promising Stocks to Buy in 2018 Motley Fool
Jan-25-18 09:38AM  Analysts Estimates for Pfizers 4Q17 Earnings Market Realist
09:02AM  Taking Stock of Arrowhead Pharmaceuticals Financial Performance Market Realist
07:32AM  What Led to Arrowhead Pharmaceuticals Revenue Surge in 2017? Market Realist
Jan-24-18 01:30PM  Arrowheads Candidates for Hepatitis B, Cardiovascular Diseases Market Realist
12:00PM  Taking a Closer Look at Arrowhead Pharmaceuticals TRIM Platform Market Realist
11:32AM  Celgene to Acquire Juno Therapeutics Market Realist
10:25AM  Analysts Recommendations for Arrowhead and Its Peers Market Realist
Jan-23-18 05:01PM  Best bets for growth at record highs CNBC Videos
04:01PM  Gilead Sciences to Release Fourth Quarter and Full Year 2017 Financial Results on Tuesday, February 6, 2018 Business Wire
11:30AM  Gilead, Parker Institute grab stakes in Penn immunotherapy spinout's $100 million round American City Business Journals
09:36AM  Celgene (CELG) to Acquire Juno Therapeutics for $9 Billion Zacks
Jan-22-18 04:23PM  Celgene Buys Juno Therapeutics: A Risky $9B Bet Forbes
03:31PM  Celgene's $9 Billion Buyout of Juno: Is It a Good Deal for Investors? Motley Fool
03:00PM  3 Stocks the World's Best Investors Are Buying Right Now Motley Fool
11:11AM  Healthcare ETFs to Watch As Q4 Earnings Unfold Zacks
Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East. The company's products include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis C virus and hepatitis B virus; hematology/oncology; cardiovascular; and inflammation/respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., Galapagos NV., and Spring Bank Pharmaceuticals, Inc. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
YOUNG KEVINChief Operating OfficerFeb 10Option Exercise0.00908016,237Feb 13 04:58 PM
WILSON GAYLE EDirectorFeb 09Option Exercise26.6260,0001,596,900182,258Feb 13 05:24 PM
WILSON GAYLE EDirectorFeb 09Sale77.9260,0004,675,080122,258Feb 13 05:24 PM
YOUNG KEVINChief Operating OfficerFeb 01Option Exercise0.00620015,547Feb 02 09:14 PM
MARTIN JOHN CExecutive ChairmanFeb 01Option Exercise23.6050,0001,180,0003,046,766Feb 05 08:38 PM
Alton Gregg HEVP,Corporate &Medical AffairsFeb 01Option Exercise40.5617,250699,66062,738Feb 05 09:20 PM
Alton Gregg HEVP,Corporate &Medical AffairsFeb 01Sale83.5125,0002,087,86037,738Feb 05 09:20 PM
MARTIN JOHN CExecutive ChairmanFeb 01Sale83.5650,0004,177,8242,996,766Feb 05 08:38 PM
Meyers James REVP Worldwide Commercial OpsJan 16Option Exercise21.58100,0002,157,500102,715Jan 18 06:31 PM
Meyers James REVP Worldwide Commercial OpsJan 16Sale80.24100,0008,024,3642,715Jan 18 06:31 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 11Option Exercise36.0225,875932,06275,488Jan 16 05:42 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 11Sale79.0030,0002,370,00045,488Jan 16 05:42 PM
MARTIN JOHN CExecutive ChairmanJan 02Option Exercise23.6050,0001,180,0003,046,766Jan 04 07:54 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 02Option Exercise24.918,625214,80664,613Jan 04 08:05 PM
MARTIN JOHN CExecutive ChairmanJan 02Sale73.6250,0003,681,2352,996,766Jan 04 07:54 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 02Sale73.8715,0001,108,01949,613Jan 04 08:05 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffDec 01Option Exercise24.918,625214,80670,988Dec 05 06:17 PM
MARTIN JOHN CExecutive ChairmanDec 01Option Exercise21.5873,3331,582,1593,070,099Dec 05 07:49 PM
MARTIN JOHN CExecutive ChairmanDec 01Sale74.9873,3335,498,3852,996,766Dec 05 07:49 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffDec 01Sale74.6415,0001,119,55255,988Dec 05 06:17 PM
MILLIGAN JOHN FPresident and CEONov 13Option Exercise21.58220,0004,746,5001,385,924Nov 15 03:19 PM
MILLIGAN JOHN FPresident and CEONov 13Sale72.88220,00016,034,6781,165,924Nov 15 03:19 PM
Meyers James REVP Worldwide Commercial OpsNov 05Option Exercise0.004,50007,215Nov 07 05:47 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffNov 01Option Exercise24.918,625214,80677,363Nov 03 06:59 PM
MARTIN JOHN CExecutive ChairmanNov 01Option Exercise21.5873,3331,582,1593,070,099Nov 03 07:04 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffNov 01Sale74.8215,0001,122,28562,363Nov 03 06:59 PM
MARTIN JOHN CExecutive ChairmanNov 01Sale75.1373,3335,509,6972,996,766Nov 03 07:04 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffOct 02Option Exercise24.9117,250429,61193,738Oct 04 07:26 PM
MARTIN JOHN CExecutive ChairmanOct 02Option Exercise21.5873,3331,582,1593,070,099Oct 04 07:19 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffOct 02Sale82.6525,0002,066,30768,738Oct 04 07:26 PM
MARTIN JOHN CExecutive ChairmanOct 02Sale82.5673,3336,054,3192,996,766Oct 04 07:19 PM
Washington Robin LEVP, CFOSep 07Option Exercise24.3033,750819,95643,352Sep 11 08:35 PM
Washington Robin LEVP, CFOSep 07Sale85.0018,0701,535,950103,477Sep 11 08:35 PM
Washington Robin LEVP, CFOSep 07Sale85.0033,7502,868,7509,602Sep 11 08:35 PM
MARTIN JOHN CExecutive ChairmanSep 01Option Exercise21.5873,3331,582,1593,070,099Sep 06 08:23 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffSep 01Option Exercise24.9117,250429,611101,488Sep 06 06:56 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffSep 01Sale83.0525,0002,076,18876,488Sep 06 06:56 PM
MARTIN JOHN CExecutive ChairmanSep 01Sale83.1173,3336,094,9922,996,766Sep 06 08:23 PM
Meyers James REVP Worldwide Commercial OpsAug 31Option Exercise21.0060,0001,260,00062,715Sep 05 05:31 PM
Meyers James REVP Worldwide Commercial OpsAug 31Sale83.1960,0004,991,2902,715Sep 05 05:31 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 30Option Exercise25.9243,1251,117,815134,238Sep 01 05:15 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 30Sale79.0050,0003,950,00084,238Sep 01 05:15 PM
YOUNG KEVINChief Operating OfficerAug 10Option Exercise0.0091007,141Aug 14 06:57 PM
Meyers James REVP Worldwide Commercial OpsAug 10Option Exercise0.0082003,535Aug 14 06:53 PM
MARTIN JOHN CExecutive ChairmanAug 01Option Exercise21.5873,3331,582,1593,199,969Aug 03 06:55 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 01Option Exercise26.998,625232,789106,113Aug 03 06:58 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 01Sale75.8815,0001,138,19091,113Aug 03 06:58 PM
MARTIN JOHN CExecutive ChairmanAug 01Sale75.8673,3335,562,7773,126,636Aug 03 06:55 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJul 21Option Exercise26.9934,500931,155137,488Jul 25 06:53 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJul 21Sale74.0040,0002,960,00097,488Jul 25 06:53 PM
MARTIN JOHN CExecutive ChairmanJul 03Option Exercise21.5873,3331,582,1593,199,969Jul 06 06:38 PM
MARTIN JOHN CExecutive ChairmanJul 03Sale71.0073,3335,206,8923,126,636Jul 06 06:38 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJul 03Sale71.065,000355,295102,988Jul 06 06:27 PM
MARTIN JOHN CExecutive ChairmanJun 01Option Exercise21.5873,3331,582,1593,273,302Jun 05 06:26 PM
MARTIN JOHN CExecutive ChairmanJun 01Sale65.2473,3334,784,5313,199,969Jun 05 06:26 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJun 01Sale65.025,000325,114107,988Jun 05 06:15 PM
Cogan John FrancisDirectorMay 09Option Exercise20.7115,000310,57562,562May 11 06:14 PM
Cogan John FrancisDirectorMay 09Sale67.259,943668,66752,619May 11 06:14 PM
MARTIN JOHN CExecutive ChairmanMay 01Option Exercise21.5873,3331,582,1593,199,969May 03 05:42 PM
MARTIN JOHN CExecutive ChairmanMay 01Sale68.3173,3335,009,4293,126,636May 03 05:42 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffMay 01Sale68.315,000341,529112,988May 03 05:41 PM
MARTIN JOHN CExecutive ChairmanApr 03Option Exercise21.5873,3331,582,1593,199,969Apr 05 05:29 PM
MARTIN JOHN CExecutive ChairmanApr 03Sale67.1873,3334,926,2873,126,636Apr 05 05:29 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffMar 30Sale67.485,000337,392117,988Apr 03 06:23 PM
MARTIN JOHN CExecutive ChairmanMar 01Option Exercise21.5873,3331,582,1593,199,969Mar 03 06:29 PM
MOORE NICHOLAS GDirectorMar 01Option Exercise0.00173012,055Mar 03 06:03 PM
MARTIN JOHN CExecutive ChairmanMar 01Sale70.3873,3335,161,2063,126,636Mar 03 06:29 PM
WILSON GAYLE EDirectorFeb 23Option Exercise20.7133,350690,512140,836Feb 27 06:29 PM
MILLIGAN JOHN FPresident and CEOFeb 23Option Exercise21.58100,0002,157,5001,165,924Feb 27 06:13 PM
WILSON GAYLE EDirectorFeb 23Sale69.3020,3651,411,374120,471Feb 27 06:29 PM